ATE538809T1 - Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff - Google Patents

Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff

Info

Publication number
ATE538809T1
ATE538809T1 AT04746847T AT04746847T ATE538809T1 AT E538809 T1 ATE538809 T1 AT E538809T1 AT 04746847 T AT04746847 T AT 04746847T AT 04746847 T AT04746847 T AT 04746847T AT E538809 T1 ATE538809 T1 AT E538809T1
Authority
AT
Austria
Prior art keywords
vaccine
selecting appropriate
biological sample
precursor cells
highly responsive
Prior art date
Application number
AT04746847T
Other languages
English (en)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Application granted granted Critical
Publication of ATE538809T1 publication Critical patent/ATE538809T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
AT04746847T 2003-06-27 2004-06-25 Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff ATE538809T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003184436 2003-06-27
JP2004070497 2004-03-12
PCT/JP2004/009378 WO2005001117A1 (ja) 2003-06-27 2004-06-25 Ｗｔ１ワクチン適応患者の選択方法

Publications (1)

Publication Number Publication Date
ATE538809T1 true ATE538809T1 (de) 2012-01-15

Family

ID=33554467

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04746847T ATE538809T1 (de) 2003-06-27 2004-06-25 Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff

Country Status (9)

Country Link
US (1) US10500257B2 (de)
EP (3) EP2338509B1 (de)
JP (1) JP4566912B2 (de)
KR (2) KR101431312B1 (de)
CN (1) CN1842603B (de)
AT (1) ATE538809T1 (de)
CA (2) CA2530184C (de)
ES (3) ES2443582T3 (de)
WO (1) WO2005001117A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1103564B1 (de) * 1998-07-31 2009-01-07 International Institute of Cancer Immunology, Inc. Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
BRPI0208183B8 (pt) 2001-03-22 2021-05-25 Sugiyama Haruo peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
ES2538486T3 (es) * 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
ES2443582T3 (es) 2003-06-27 2014-02-19 International Institute Of Cancer Immunology, Inc. Método para diagnosticar el cáncer que comprende la medición de las células precursoras de CTL específicos de WT1
CN101580538B (zh) 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
ES2556232T3 (es) * 2004-03-31 2016-01-14 International Institute Of Cancer Immunology, Inc. Péptidos antigénicos del cáncer derivados de WT1
CA2593714C (en) * 2005-02-04 2013-09-10 Survac Aps Survivin peptide vaccine
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
WO2007063903A1 (ja) * 2005-11-30 2007-06-07 International Institute Of Cancer Immunology, Inc. 新規ペプチド化合物
EP3117836A1 (de) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogene wt-1-peptide und verwendungen davon
EP2390360A1 (de) * 2006-06-02 2011-11-30 GlaxoSmithKline Biologicals S.A. Verfahren zur Indentifizierung des Ansprechens bzw. Nichtansprechens eines Patienten auf eine Immuntherapie basierend auf die Differentielle Expression vom Gen IDO1
BRPI0808084A2 (pt) 2007-02-27 2014-07-22 Int Inst Cancer Immunology Inc Método para ativação de células t auxiliadoras e composição para uso no método.
WO2008108257A1 (ja) * 2007-03-05 2008-09-12 International Institute Of Cancer Immunology, Inc. 癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用
CA2940962C (en) * 2007-12-05 2018-07-24 International Institute Of Cancer Immunology, Inc. Cancer vaccine composition
EP2626418B8 (de) 2010-10-05 2021-03-24 International Institute of Cancer Immunology, Inc. Verfahren zur aktivierung von t-helferzellen
CN103764826A (zh) 2011-06-28 2014-04-30 株式会社癌免疫研究所 肽癌抗原-特异性t细胞的受体基因
EP2561759A1 (de) 2011-08-26 2013-02-27 Bayer Cropscience AG Fluoralkyl-substituierte 2-amidobenzimidazole und ihre Wirkung auf das Pflanzenwachstum
US10301257B2 (en) 2011-09-16 2019-05-28 Bayer Intellectual Property Gmbh Use of acylsulfonamides for improving plant yield
IN2014CN01860A (de) 2011-09-16 2015-05-29 Bayer Ip Gmbh
CA2848622A1 (en) 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh Use of 5-phenyl- or 5-benzyl-2-isoxazoline-3-carboxylates for improving plant yield
HK1204261A1 (en) 2012-01-13 2015-11-13 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
KR20150092122A (ko) 2012-10-23 2015-08-12 프로비던스 헬스 앤드 서비시즈, 오레곤 질환 치료용 동종 자가포식소체-강화된 조성물
CA2892660C (en) 2012-12-17 2022-02-15 Otsuka Pharmaceutical Co., Ltd. Method for activating helper t cell
PT2945647T (pt) * 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
JP6396339B2 (ja) 2013-03-05 2018-09-26 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 植物の収量を向上させるためのキノリン誘導体の使用
ES2748350T3 (es) 2013-03-05 2020-03-16 Bayer Cropscience Ag Uso de N-(2-metoxibenzoil)-4-[metilaminocarbonil)amino]bencenosulfonamida en combinación con un insecticida o fungicida para mejorar el rendimiento en plantas
JP6469074B2 (ja) * 2013-03-28 2019-02-13 サントル オスピタリエ ユニヴェルシテール ド モンペリエ 放射線感受性を判定するための方法
WO2014185387A1 (ja) * 2013-05-13 2014-11-20 株式会社癌免疫研究所 免疫療法の臨床効果の予測法
EP4130026A1 (de) 2015-11-20 2023-02-08 Memorial Sloan-Kettering Cancer Center Verfahren und zusammensetzungen zum behandeln von krebs
EP3318135A1 (de) 2016-11-03 2018-05-09 Perfetti Van Melle S.p.A. Sprudelndes süssigkeitenmaterial, verfahren zu dessen herstellung und daraus hergestellte produkte
EP3728317A2 (de) 2017-12-21 2020-10-28 F. Hoffmann-La Roche AG An hla-a2/wt1 bindende antikörper
WO2021230247A1 (ja) * 2020-05-12 2021-11-18 大日本住友製薬株式会社 癌を処置するための医薬組成物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923799A (en) 1984-02-06 1990-05-08 The Ontario Cancer Institute T cell specific cDNA clone
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
CA2116526A1 (en) 1991-08-28 1993-03-18 William V. Williams T cell receptor-based therapy for rheumatoid arthritis
US5364787A (en) 1992-03-23 1994-11-15 Idaho Research Foundation Genes and enzymes involved in the microbial degradation of pentachlorophenol
KR100262838B1 (ko) * 1996-04-16 2003-03-15 기시모토 다다미쓰 고형암세포및조직이형성의검출방법,및골수이식및말초혈간세포이식용조직의검사방법
GB9710820D0 (en) 1997-05-27 1997-07-23 Univ Dundee Immunological method
US6013444A (en) 1997-09-18 2000-01-11 Oligotrail, Llc DNA bracketing locus compatible standards for electrophoresis
AU5528198A (en) 1997-12-03 1999-06-16 Immune Response Corporation, The Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
AU758949B2 (en) 1998-05-19 2003-04-03 Avidex Limited Multivalent T cell receptor complexes
EP1103564B1 (de) 1998-07-31 2009-01-07 International Institute of Cancer Immunology, Inc. Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
PL201881B1 (pl) 1998-09-30 2009-05-29 Corixa Corp Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
AU774952B2 (en) 1999-02-23 2004-07-15 Baylor College Of Medicine T cell receptor Vbeta-Dbeta-Jbeta sequence and methods for its detection
AU2001265346A1 (en) * 2000-06-02 2001-12-17 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
AU2002222610A1 (en) 2000-12-13 2002-06-24 Sumitomo Pharmaceuticals Company, Limited Transgenic animal expressing hla-a24 and utilization thereof
BRPI0208183B8 (pt) 2001-03-22 2021-05-25 Sugiyama Haruo peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
CA2451846A1 (en) 2001-06-29 2003-01-09 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine comprizing a cancer antigen based on the product of a tumor suppressor gene wt1 and a cationic liposome
EP1473564A4 (de) * 2001-09-18 2008-12-10 Greenpeptide Co Ltd Verfahren zum nachweis von zellimmunität und dessen anwendung auf arzneistoffe
WO2003028758A1 (en) 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003028757A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003059155A2 (en) 2002-01-09 2003-07-24 Maxx Genetech Co. Ltd Method of detecting t-cell proliferation for diagnosis of diseases by gene array
KR101050703B1 (ko) * 2002-06-12 2011-07-20 추가이 세이야쿠 가부시키가이샤 Ｈｌａ-ａ24-구속성 암 항원 펩티드
ES2538486T3 (es) * 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
WO2004063706A2 (en) 2003-01-08 2004-07-29 Maxx Genetech Co., Ltd. Method of detecting over-expression of t-cell receptor genes by real-time pcr
ES2443582T3 (es) 2003-06-27 2014-02-19 International Institute Of Cancer Immunology, Inc. Método para diagnosticar el cáncer que comprende la medición de las células precursoras de CTL específicos de WT1
CN101580538B (zh) * 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
US20070238099A1 (en) 2003-12-08 2007-10-11 Cohen Irun R Antigen Receptor Variable Region Typing
US7576183B2 (en) 2003-12-24 2009-08-18 Los Alamos National Security, Llc Structure-based receptor MIMICS targeted against bacterial superantigen toxins
ES2556232T3 (es) * 2004-03-31 2016-01-14 International Institute Of Cancer Immunology, Inc. Péptidos antigénicos del cáncer derivados de WT1
GB0411771D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Nucleoproteins displaying native T cell receptor libraries
GB0427585D0 (en) 2004-12-16 2005-01-19 Avidex Ltd Assay
WO2008026927A2 (en) 2006-08-30 2008-03-06 Academisch Medisch Centrum Process for displaying t- and b-cell receptor repertoires
WO2008108257A1 (ja) 2007-03-05 2008-09-12 International Institute Of Cancer Immunology, Inc. 癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用
JP2009278927A (ja) 2008-05-23 2009-12-03 Tohoku Univ Ｔ細胞受容体を模倣する抗体断片及びその製造方法
CN103764826A (zh) 2011-06-28 2014-04-30 株式会社癌免疫研究所 肽癌抗原-特异性t细胞的受体基因

Also Published As

Publication number Publication date
KR101431312B1 (ko) 2014-08-20
EP1640458A1 (de) 2006-03-29
WO2005001117A1 (ja) 2005-01-06
KR101292971B1 (ko) 2013-08-12
CN1842603B (zh) 2013-09-11
EP1640458A4 (de) 2008-05-21
EP2338509A2 (de) 2011-06-29
KR20060069363A (ko) 2006-06-21
EP2343083A2 (de) 2011-07-13
EP2338509A3 (de) 2011-11-30
ES2443582T3 (es) 2014-02-19
JPWO2005001117A1 (ja) 2006-08-10
ES2478446T3 (es) 2014-07-22
EP2343083B1 (de) 2014-01-15
CA2893995A1 (en) 2005-01-06
EP2343083A3 (de) 2011-08-03
KR20110049877A (ko) 2011-05-12
US20070128207A1 (en) 2007-06-07
EP1640458B1 (de) 2011-12-28
US10500257B2 (en) 2019-12-10
CN1842603A (zh) 2006-10-04
CA2530184C (en) 2015-10-06
CA2530184A1 (en) 2005-01-06
JP4566912B2 (ja) 2010-10-20
EP2338509B1 (de) 2014-06-18
ES2378156T3 (es) 2012-04-09
HK1090093A1 (en) 2006-12-15

Similar Documents

Publication Publication Date Title
ATE538809T1 (de) Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff
ATE399323T1 (de) Verfahren zur bestimmung von amyloidogenen proteinen
ATE465632T1 (de) Verfahren und gerät zur identifikation von lebendigen eiern mittels pulsfrequenz und embryobewegung
ATE520979T1 (de) Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
SG10201804260QA (en) Diagnostic assays and kits for detection of folate receptor 1
RU2007141067A (ru) Терапия с помощью антител к egfr, основанная на повышенном числе копий гена egfr в опухолевых тканях
NO20074389L (no) Bestemmelse av respondere til kjemoterapi
DE60129151D1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
ATE514951T1 (de) Verfahren zur prüfung eines mehrkanaligen elements zur blutanalyse
JP2014512006A5 (de)
Lu et al. Pro-inflammatory effect of fibrinogen and FDP on vascular smooth muscle cells by IL-6, TNF-α and iNOS
TW200636076A (en) Method for measuring resistance or sensitivity to docetaxel
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
ATE184703T1 (de) Verfahren und testsatz zur messung von endogenen zytokinen
EA201170365A1 (ru) Способ и устройство диагностики и скрининга заболеваний с использованием электромагнитных полей сверхнизкой частоты
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
JP5866053B1 (ja) 皮膚粘弾性のマーカー及びその利用
AR071034A1 (es) Uso de la catepsina c en el diagnostico de susceptibilidad al dolor y para el tratamiento del dolor
ATE550668T1 (de) Verfahren zur identifizierung von patienten mit erhöhtem risiko für ein unerwünschtes herz- kreislauf-ereignis
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
DE60025170D1 (de) Diagnostisches verfahren für asthma
FI20040255A7 (fi) Menetelmä pre-eklampsian riskin havaitsemiseksi
DE10391021D2 (de) Verfahren zur Charakterisierung hochparallelisierter Liquidhandlingtechnik mittels Mikroplatten sowie Testkit zur Durchführung des Verfahrens
RU2011142612A (ru) Биомаркер для мониторинга пациентов
ATE547534T1 (de) Verfahren zur nichtinvasiven untersuchung nicht- alkoholischer steatohepatitis mittels quantifizierung von cytochrom-c